Milan

• A Phase 3 Study Comparing Pirtobrutinib to Ibrutinib in CLL/SLL Recruiting
  2023-507699-38-00 5 2022-08-30 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Sele … Recruiting
  2024-512822-28-00 1 2022-08-08 Advanced or metastatic solid tumors
• An outpatient study to learn if Staccato Alprazolam is safe and effective when treating long seizures in children ≥12 years of age and adult … Recruiting
  2024-510950-29-00 5 2022-07-21 Stereotypical prolonged seizure
• A study to evaluate efficacy and safety of an investigational drug named volixibat in patients with itching caused by primary biliary cholan … Recruiting
  2023-504660-41-00 4 2022-07-11 Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (PBC
• An Open Label, Phase 2 Study to Evaluate Activity and Safety of Daratumumab in combination with Bortezomib and Dexamethasone in patients wit … Recruiting
  2024-511635-94-00 4 2022-07-11 Relapsed or Refractory Plasmablastic lymphoma
• Effects of ozanimod on myelin dynamics and neurodegeneration in patients with relapsingremitting multiple sclerosis: correlation with diseas … Recruiting
  2024-513960-24-00 6 2022-06-22 Multiple sclerosis patients in relapse and remission form
• Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy Recruiting
  2024-511201-32-00 5 2022-06-13 Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
• Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable Non-small Cell Lung Cancer Recruiting
  2023-508852-21-00 4 2022-06-10 Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer
• A clinical study to learn about the safety and effects of KIN-2787, a new oral anticancer drug for the treatment of patients with BRAF and/o … Recruiting
  2024-516331-27-00 3 2022-06-10 Participants with BRAF and/or NRAS mutation positive tumors
• A Phase 1/2 Study of BMS-986340 with and without Nivolumab or Docetaxel in Solid Tumors Recruiting
  2023-503651-10-00 7 2022-05-17 Male and female participants ≥ 18 years of age with advanced or metast
• Brigatinib in pediatric and young adult patients with ALK+ ALCL, IMT or other solid tumors (Briga-PED) Recruiting
  2024-513412-10-00 9 2022-05-11 Anaplastic Large Cell Lymphoma (ALCL)
• Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minima … Recruiting
  2024-515681-14-00 4 2022-05-02 Stage II (pT4)/III colorectal cancer with positive circulating tumor D
• A study of MK-7240/PRA023 in patients with Systemic Sclerosis Associated with Interstitial Lung Disease Recruiting
  2023-509743-27-00 4 2022-04-29 Systemic sclerosis associated with interstitial lung disease
• Efficacy and safety of subcutaneous dupilumab for the treatment of adult participants with chronic pruritus of unknown origin (CPUO) Recruiting
  2023-508879-36-00 5 2022-04-28 Pruritus
• Study of the genetic, viral and immune response characteristics of a group of patients infected with the AIDS virus treated early and then s … Recruiting
  2024-515419-24-00 6 2022-04-27 HIV-1 positive subjects treated with effective antiretroviral therapy
• FI-3, Fidelia Recruiting
  2024-518243-38-00 5 2022-04-20 Fecal incontinence in female and male patients
• Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting
  2022-502425-18-00 5 2022-04-19 Adenocarcinoma of the prostate
• A phase I study of the mesothelin x cd47 antibody NI-1801, as single agent and in combination with anti-pd-1 antibody, or with paclitaxel al … Recruiting
  2024-517752-35-00 1 2022-04-04 Advanced, metastatic, or recurrent solid mesothelin-expressing maligna
• A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer … Recruiting
  2024-512089-32-00 3 2022-03-28 Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
• Study of BGB-11417 in Patients with Myeloid Malignancies Recruiting
  2023-508881-14-00 9 2022-03-21 Myeloid malignancies (acute myeloid leukemia (AML), myelodysplastic sy
• A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1) Recruiting
  2024-511793-71-00 7 2022-02-28 Advanced ROS1-positive NSCLC and other advanced ROS1-positive solid tu
• Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants with Myotonic Dystrophy Type 1 Recruiting
  2023-510353-42-00 7 2022-02-21 Myotonic Dystrophy Type 1
• A study to evaluate long-term Infigratinib in children with Achondroplasia Recruiting
  2024-513857-55-00 4 2022-02-08 Achondroplasia
• Evaluation of an initial treatment with bevacizumab in combination with chemotherapy and then in combination with niraparib in maintenance i … Recruiting
  2023-504166-37-00 4 2022-02-01 Advanced ovarian, tubal or peritoneal cancer.

Showing 1,105–1,128 of 2,361 trials